Zonisamide for Weight Reduction in Obese Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00275834
Recruitment Status : Completed
First Posted : January 12, 2006
Results First Posted : January 16, 2013
Last Update Posted : January 12, 2017
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Duke University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Obesity
Intervention: Drug: Zonisamide

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study was conducted at Duke University Medical Center between 2006 and 2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants are considered to have completed the study if they returned for final study visit. The number completed represents participants who stayed on study drug during the trial plus participants who discontinued study drug during the trial but continued to be followed by study team and completed the final visit assessments.

Reporting Groups

Zonisamide 100 mg and placebo capsules were prepared in accordance with Good Manufacturing Practice (GMP) guidelines in Duke Compounding Facility with active pharmaceutical ingredient (Sochinaz SA, Switzerland, distributed by Bachem Americas, King of Prussia, Pennsylvania) plus dextrose as an inactive ingredient. Identical-looking placebo capsules contained dextrose.

Each capsule contained zonisamide 100 mg or placebo, with patients and study staff blinded to contents. Dose was gradually titrated upward as follows: 1 capsule for 15 days, 2 during days 16-30, 3 capsules during days 31-45, and 4 from day 46 onward. The entire dose was taken at night. Blinded dose reduction was allowed and dose increase could be withheld. Patients had the option to discontinue the drug and remain in the study receiving only diet and lifestyle counseling.

Zonisamide 200 mg Dosing of matching placebo was identical.
Zonisamide 400 mg No text entered.

Participant Flow:   Overall Study
    Placebo   Zonisamide 200 mg   Zonisamide 400 mg
STARTED   74   76   75 
Completed Study While on Study Drug   54   51   62 
COMPLETED   71   73   74 
NOT COMPLETED   3   3   1 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Placebo No text entered.
Zonisamide 200 mg No text entered.
Zonisamide 400 mg No text entered.
Total Total of all reporting groups

Baseline Measures
   Placebo   Zonisamide 200 mg   Zonisamide 400 mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 74   76   75   225 
[Units: Participants]
Count of Participants
<=18 years      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      74 100.0%      76 100.0%      75 100.0%      225 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
[Units: Years]
Mean (Standard Deviation)
 43.5  (10.3)   44.2  (10.1)   42.3  (10.0)   43.4  (10.1) 
[Units: Participants]
Count of Participants
Female      44  59.5%      45  59.2%      45  60.0%      134  59.6% 
Male      30  40.5%      31  40.8%      30  40.0%      91  40.4% 
Region of Enrollment 
[Units: Participants]
United States   74   76   75   225 

  Outcome Measures

1.  Primary:   Change in Body Weight   [ Time Frame: 1 year ]

2.  Secondary:   Proportions of Patients With 5% Weight Loss   [ Time Frame: 1 year ]

3.  Secondary:   Proportions of Patients With 10% Weight Loss   [ Time Frame: 1 year ]

4.  Secondary:   Waist Circumference   [ Time Frame: 1 year ]

5.  Secondary:   Inflammatory Markers (CRP)   [ Time Frame: 1 year ]

6.  Secondary:   Change in Lipids   [ Time Frame: baseline, 1 year ]

7.  Secondary:   Quality of Life as Measured by HADS_D   [ Time Frame: 1 year ]

8.  Secondary:   Change in Blood Pressure   [ Time Frame: Baseline, 1 year ]

  Serious Adverse Events

Time Frame 1-year
Additional Description No text entered.

Reporting Groups
Placebo No text entered.
Zonisamide 200 mg No text entered.
Zonisamide 400 mg No text entered.

Serious Adverse Events
    Placebo   Zonisamide 200 mg   Zonisamide 400 mg
Total, Serious Adverse Events       
# participants affected / at risk   0/74 (0.00%)   0/76 (0.00%)   0/75 (0.00%) 

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information